Cyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Multicenter, Randomized, Double-Masked, Phase III, COSMO Trial

References

• Shimazaki J. Definition and diagnostic criteria of dry eye disease: historical overview and future directions. Invest Ophthalmol Vis Sci. 2018;59:DES7–DES12.
   PubMed Web of Science ®Google Scholar
• Chinese Branch of the Asian Dry Eye Society, Ocular Surface and Tear Film Diseases Group of Ophthalmology Committee of Cross-Straits Medicine Exchange Association, Ocular Surface and Dry Eye Group of Chinese Ophthalmologist Association. Chinese expert consensus on dry eye: definition and classification (2020). Zhonghua Yan Ke Za Zhi. 2020;56:418–422.
   Google Scholar
• American Academy of Ophthalmology. Preferred Practice Pattern (PPP) Guideline. Dry eye syndrome. San Francisco: American Academy of Ophthalmology; 2018. Available from: https://www.aao.org/preferred-practice-pattern/dry-eye-syndrome-ppp-2018. Accessed January 13, 2022.
   Google Scholar
• Clayton JA. Dry eye. N Engl J Med. 2018;378(23):2212–2223. doi:10.1056/NEJMra1407936
   PubMed Web of Science ®Google Scholar
• Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15(4):802–812. doi:10.1016/j.jtos.2017.08.003
   PubMed Web of Science ®Google Scholar
• Rhee MK, Mah FS. Inflammation in dry eye disease: how do we break the cycle? Ophthalmology. 2017;124(11):S14–S9. doi:10.1016/j.ophtha.2017.08.029
   PubMed Web of Science ®Google Scholar
• Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3):438–510. doi:10.1016/j.jtos.2017.05.011
   PubMed Web of Science ®Google Scholar
• Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276–283. doi:10.1016/j.jtos.2017.05.008
   PubMed Web of Science ®Google Scholar
• Schultz C. Safety and efficacy of cyclosporine in the treatment of chronic dry eye. Ophthalmol Eye Dis. 2014;6:37–42. doi:10.4137/OED.S16067
   PubMedGoogle Scholar
• Kymionis GD, Bouzoukis DI, Diakonis VF, Siganos C. Treatment of chronic dry eye: focus on cyclosporine. Clin Ophthalmol. 2008;2:829–836. doi:10.2147/OPTH.S1409
   PubMedGoogle Scholar
• Perry HD, Solomon R, Donnenfeld ED, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol. 2008;126(8):1046–1050. doi:10.1001/archopht.126.8.1046
   PubMedGoogle Scholar
• de Paiva CS, Pflugfelder SC, Ng SM, Akpek EK. Topical cyclosporine A therapy for dry eye syndrome. Cochrane Database Syst Rev. 2019;9:CD010051. doi:10.1002/14651858.CD010051.pub2
   PubMed Web of Science ®Google Scholar
• Periman LM, Mah FS, Karpecki PM. A review of the mechanism of action of cyclosporine A: the role of cyclosporine A in dry eye disease and recent formulation developments. Clin Ophthalmol. 2020;14:4187–4200. doi:10.2147/OPTH.S279051
   PubMed Web of Science ®Google Scholar
• Society CBotADE, Association OSaTFDGoOCoC-SME, Association OSaDEGoCO. Chinese expert consensus on dry eye: treatment (2020). Zhonghua Yan Ke Za Zhi. 2020;56:907–913.
   Google Scholar
• Akpek EK, Amescua G, Farid M, et al. Dry eye syndrome preferred practice pattern®. Ophthalmology. 2019;126(1):P286–P334. doi:10.1016/j.ophtha.2018.10.023
   PubMed Web of Science ®Google Scholar
• Periman LM, Perez VL, Saban DR, Lin MC, Neri P. The immunological basis of dry eye disease and current topical treatment options. J Ocul Pharmacol Ther. 2020;36(3):137–146. doi:10.1089/jop.2019.0060
   PubMed Web of Science ®Google Scholar
• Mah F, Milner M, Yiu S, Donnenfeld E, Conway TM, Hollander DA. PERSIST: physician’s evaluation of Restasis(®) satisfaction in second trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review. Clin Ophthalmol. 2012;6:1971–1976. doi:10.2147/OPTH.S30261
   PubMedGoogle Scholar
• Allergan Inc. Product monograph. restasis multidose, cyclosporine ophthalmic emulsion, 0.05% w/v; 2018. Available from: https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/9054xmd-2018jun01-en-restasis-multidose.pdf. Accessed January 13, 2022.
   Google Scholar
• de Oliveira RC, Wilson SE. Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease. Clin Ophthalmol. 2019;13:1115–1122. doi:10.2147/OPTH.S184412
   PubMed Web of Science ®Google Scholar
• Peng W-Y, Chen R-X, Dai H, et al. Efficacy, safety, and tolerability of a novel cyclosporine, a formulation for dry eye disease: a multicenter phase II clinical study. Clin Ther. 2021;43(3):613–628. doi:10.1016/j.clinthera.2020.12.023
   Web of Science ®Google Scholar
• Woods J, Hutchings N, Srinivasan S, Jones L. Geographic distribution of corneal staining in symptomatic dry eye. Ocul Surf. 2020;18(2):258–266. doi:10.1016/j.jtos.2019.07.009
   Web of Science ®Google Scholar
• Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 Phase 3 study. Ophthalmology. 2014;121(2):475–483. doi:10.1016/j.ophtha.2013.09.015
   PubMed Web of Science ®Google Scholar
• Tauber J, Karpecki P, Latkany R, et al. Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study. Ophthalmology. 2015;122(12):2423–2431. doi:10.1016/j.ophtha.2015.08.001
   PubMed Web of Science ®Google Scholar
• Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 study group. Ophthalmology. 2000;107(4):631–639. doi:10.1016/S0161-6420(99)00176-1
   PubMed Web of Science ®Google Scholar
• Leonardi A, Messmer EM, Labetoulle M, et al. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies. Br J Ophthalmol. 2019;103(1):125–131. doi:10.1136/bjophthalmol-2017-311801
   Web of Science ®Google Scholar
• Sheppard JD, Wirta DL, McLaurin E, et al. A water-free 0.1% cyclosporine A solution for treatment of dry eye disease: results of the randomized phase 2B/3 ESSENCE study. Cornea. 2021;40(10):1290–1297. doi:10.1097/ICO.0000000000002633
   PubMed Web of Science ®Google Scholar
• Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD. A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease. Ophthalmology. 2019;126(9):1230–1237. doi:10.1016/j.ophtha.2019.03.050
   PubMed Web of Science ®Google Scholar
• Kang M-J, Kim Y-H, Chou M, et al. Evaluation of the efficacy and safety of A novel 0.05% cyclosporin A topical nanoemulsion in primary Sjögren’s syndrome dry eye. Ocul Immunol Inflamm. 2020;28(3):370–378. doi:10.1080/09273948.2019.1587470
   PubMed Web of Science ®Google Scholar
• Hovanesian JA, Nichols KK, Jackson M, et al. Real-world experience with lifitegrast ophthalmic solution (Xiidra) in the US and Canada: retrospective study of patient characteristics, treatment patterns, and clinical effectiveness in 600 patients with dry eye disease. Clin Ophthalmol. 2021;15:1041–1054. doi:10.2147/OPTH.S296510
   Web of Science ®Google Scholar
• Baudouin C, de la Maza MS, Amrane M, et al. One-year efficacy and safety of 0.1% cyclosporine a cationic emulsion in the treatment of severe dry eye disease. Eur J Ophthalmol. 2017;27(6):678–685. doi:10.5301/ejo.5001002
   PubMed Web of Science ®Google Scholar
• Thulasi P, Djalilian AR. update in current diagnostics and therapeutics of dry eye disease. Ophthalmology. 2017;124(11):S27–S33. doi:10.1016/j.ophtha.2017.07.022
   Web of Science ®Google Scholar